drugset / Trial / NCT01674855

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

NCT01674855

Phase 3 Completed 74 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.

Timeline

Start
2012-02
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator G-CSF Unknown 100 ug/m2
Subject Pegfilgrastim Protein / enzyme biologic 6 mg

Indications